161 related articles for article (PubMed ID: 25258022)
1. Predictors for resectability and survival in locally advanced pancreatic cancer after gemcitabine-based neoadjuvant therapy.
Chao YJ; Sy ED; Hsu HP; Shan YS
BMC Surg; 2014 Sep; 14():72. PubMed ID: 25258022
[TBL] [Abstract][Full Text] [Related]
2. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience.
Leone F; Gatti M; Massucco P; Colombi F; Sperti E; Campanella D; Regge D; Gabriele P; Capussotti L; Aglietta M
Cancer; 2013 Jan; 119(2):277-84. PubMed ID: 22778019
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer.
Combs SE; Habermehl D; Kessel KA; Bergmann F; Werner J; Naumann P; Jäger D; Büchler MW; Debus J
Ann Surg Oncol; 2014 Aug; 21(8):2801-7. PubMed ID: 24916745
[TBL] [Abstract][Full Text] [Related]
4. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma.
OʼReilly EM; Perelshteyn A; Jarnagin WR; Schattner M; Gerdes H; Capanu M; Tang LH; LaValle J; Winston C; DeMatteo RP; DʼAngelica M; Kurtz RC; Abou-Alfa GK; Klimstra DS; Lowery MA; Brennan MF; Coit DG; Reidy DL; Kingham TP; Allen PJ
Ann Surg; 2014 Jul; 260(1):142-8. PubMed ID: 24901360
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival.
Allendorf JD; Lauerman M; Bill A; DiGiorgi M; Goetz N; Vakiani E; Remotti H; Schrope B; Sherman W; Hall M; Fine RL; Chabot JA
J Gastrointest Surg; 2008 Jan; 12(1):91-100. PubMed ID: 17786524
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer.
Habermehl D; Kessel K; Welzel T; Hof H; Abdollahi A; Bergmann F; Rieken S; Weitz J; Werner J; Schirmacher P; Büchler MW; Debus J; Combs SE
Radiat Oncol; 2012 Mar; 7():28. PubMed ID: 22385572
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Response and Survival in Locally Advanced Adenocarcinoma of the Pancreas Following Neoadjuvant GTX with or Without Radiation Therapy.
Sherman WH; Hecht E; Leung D; Chu K
Oncologist; 2018 Jan; 23(1):4-e10. PubMed ID: 29212734
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?
Chen KT; Devarajan K; Milestone BN; Cooper HS; Denlinger C; Cohen SJ; Meyer JE; Hoffman JP
Ann Surg Oncol; 2014 Feb; 21(2):662-9. PubMed ID: 24276638
[TBL] [Abstract][Full Text] [Related]
9. Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis.
Mayahara H; Ito Y; Morizane C; Ueno H; Okusaka T; Kondo S; Murakami N; Morota M; Sumi M; Itami J
BMC Cancer; 2012 Dec; 12():609. PubMed ID: 23256481
[TBL] [Abstract][Full Text] [Related]
10. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
[TBL] [Abstract][Full Text] [Related]
11. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH
Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366
[TBL] [Abstract][Full Text] [Related]
12. Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer.
Paik WH; Lee SH; Kim YT; Park JM; Song BJ; Ryu JK
J Korean Med Sci; 2015 Jul; 30(7):917-23. PubMed ID: 26130955
[TBL] [Abstract][Full Text] [Related]
13. Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection.
Gemenetzis G; Groot VP; Blair AB; Laheru DA; Zheng L; Narang AK; Fishman EK; Hruban RH; Yu J; Burkhart RA; Cameron JL; Weiss MJ; Wolfgang CL; He J
Ann Surg; 2019 Aug; 270(2):340-347. PubMed ID: 29596120
[TBL] [Abstract][Full Text] [Related]
14. Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy.
Wijetunga AR; Chua TC; Nahm CB; Pavlakis N; Clarke S; Chan DL; Diakos C; Maloney S; Ashrafi-Zadeh A; Kneebone A; Hruby G; Jamieson NB; Gill A; Mittal A; Samra JS
Eur J Surg Oncol; 2021 Oct; 47(10):2543-2550. PubMed ID: 33952409
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?
Bednar F; Zenati MS; Steve J; Winters S; Ocuin LM; Bahary N; Hogg ME; Zeh HJ; Zureikat AH
Ann Surg Oncol; 2017 May; 24(5):1406-1413. PubMed ID: 27896518
[TBL] [Abstract][Full Text] [Related]
16. Pancreatectomy with major arterial resection after neoadjuvant chemoradiotherapy gemcitabine and S-1 and concurrent radiotherapy for locally advanced unresectable pancreatic cancer.
Amano R; Kimura K; Nakata B; Yamazoe S; Motomura H; Yamamoto A; Tanaka S; Hirakawa K
Surgery; 2015 Jul; 158(1):191-200. PubMed ID: 25900035
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer.
Patel M; Hoffe S; Malafa M; Hodul P; Klapman J; Centeno B; Kim J; Helm J; Valone T; Springett G
J Surg Oncol; 2011 Aug; 104(2):155-61. PubMed ID: 21520097
[TBL] [Abstract][Full Text] [Related]
18. Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort.
Walma MS; Brada LJ; Patuleia SIS; Blomjous JG; Bollen TL; Bosscha K; Bruijnen RC; Busch OR; Creemers GJ; Daams F; van Dam R; Festen S; Jan de Groot D; Willem de Groot J; Mohammad NH; Hermans JJ; de Hingh IH; Kerver ED; van Leeuwen MS; van der Leij C; Liem MS; van Lienden KP; Los M; de Meijer VE; Meijerink MR; Mekenkamp LJ; Nederend J; Nio CY; Patijn GA; Polée MB; Pruijt JF; Renken NS; Rombouts SJ; Schouten TJ; Stommel MWJ; Verweij ME; de Vos-Geelen J; de Vries JJJ; Vulink A; Wessels FJ; Wilmink JW; van Santvoort HC; Besselink MG; Molenaar IQ;
Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):699-707. PubMed ID: 33280952
[TBL] [Abstract][Full Text] [Related]
19. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.
Evans DB; Varadhachary GR; Crane CH; Sun CC; Lee JE; Pisters PW; Vauthey JN; Wang H; Cleary KR; Staerkel GA; Charnsangavej C; Lano EA; Ho L; Lenzi R; Abbruzzese JL; Wolff RA
J Clin Oncol; 2008 Jul; 26(21):3496-502. PubMed ID: 18640930
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection.
Wolfe AR; Prabhakar D; Yildiz VO; Cloyd JM; Dillhoff M; Abushahin L; Alexandra Diaz D; Miller ED; Chen W; Frankel WL; Noonan A; Williams TM
Cancer Med; 2020 Jul; 9(13):4711-4723. PubMed ID: 32415696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
